Biography

“Any sufficiently advanced technology is indistinguishable from magic.” This perspective by Arthur C. Clarke resonated with me during my undergraduate studies in Natural Sciences at University College London. Initially interested in drug design, my research on antibody-drug conjugates (ADCs) led me to realise that therapeutic efficacy is not solely determined by the drug itself, but by how precisely its delivery, targeting and release can be controlled. This led me to see drug delivery not just as a biological challenge, but as an engineering problem - one of designing and controlling molecular architecture, interactions and functions at the nanoscale. With antimicrobial resistance threatening modern medicine, my PhD will focus on engineering programmable drug delivery systems using DNA nanotechnology to target drug-resistant bacteria such as MRSA strains. By improving where and when antimicrobial agents act, this approach aims to enhance efficacy while limiting non-specific exposure that drives resistance. I look forward to working within the Gates community to translate these ideas into real-world solutions that improve lives globally, advancing more precise, accessible and equitable antimicrobial therapies.

Previous Education

University of Cambridge Pharmacology 2026
University College London Natural Sciences (Biomed&Chem) 2025